Studies Find Avastin Can Stabilize Tumors in Ovarian Cancer
read more

EU Approves Avastin for Ovarian Cancer
read more

New Funds Approved for Ovarian Cancer Research
read more

Oophorectomy before age 45 could mean lower bone mineral density
read more

Chemo Combo Kills Resistant Ovarian Cancer Cells
read more

Study Shows Ovarian Cancer May Be Tied To Fertility Treatments
read more

Information on Doxil Shortage
read more

New Breakthrough For Ovarian Cancer Surgeries
read more

NOCC hosts awareness luncheon with Shannon Miller
read more

NOCC partners with The Dr. Oz Show for episode on ovarian cancer
read more

Dr. Oz and NOCC provide fact sheet for women to bring to doctors
read more

FDA Clears Biomarker Test For Women With Adnexal Ovarian Mass
Fujirebio Diagnostics has recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the company’s HE4 Test in an algorithm called ROMA™ (HE4 EIA + ARCHITECT CA 125 IITM)* to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy on surgery.

The ROMA (Risk of Ovarian Malignancy Algorithm) test uses the results from simple blood tests, CA125 and HE4, to identify patients presenting with adnexal mass as high or low likelihood for finding malignancy on surgery. HE4 has been shown to be elevated in epithelial ovarian cancers (EOC), the most common type of ovarian cancer, but is not elevated in many benign gynecologic diseases. Combining physician assessment with the independently validated ROMA algorithm enables physicians to identify those patients at high likelihood of malignancy who should have their surgery performed by a gynecologic oncologist.

 “Using ROMA with HE4 and CA125 significantly improves our ability to identify women who are at high or low likelihood of having ovarian cancer when they present with an ovarian cyst or mass,” said Richard G. Moore, MD, Associate Professor of Obstetrics and Gynecology at the Alpert School of Medicine at Brown University and Director of the Center for Biomarkers and Emerging Technologies in the Program for Women’s Oncology at Women and Infants’ Hospital in Providence, RI. “Patients who have ovarian cancer have better outcomes when their surgery is performed by a gynecologic oncologist at centers experienced in the management of this disease. This combination test will allow physicians to identify those patients who should be treated by a gynecologic oncologist and equally important allow women with benign disease to stay in their communities with the physician who knows them best. It will change the way doctors diagnose and treat ovarian cancer,” added Dr. Moore, who is the lead researcher for the team that developed ROMA and author of two multi-center studies investigating the use of HE4 and CA125 and ROMA.

Ovarian cancer is recognized as difficult to diagnose because its symptoms are easily confused with other non-cancerous conditions. Three quarters of cases of ovarian cancer are diagnosed at an advanced stage, when it is more difficult to treat. Of patients who are diagnosed early (Stage I-II), more than 90 percent will live past five years. However, only one quarter of cases are diagnosed in the early stages.

“The clearance of ROMA is a major advance for the gynecologist and will become an important component of the preoperative assessment of women presenting with a pelvic mass,” said Lee P. Shulman, MD, Professor of Obstetrics and Gynecology, Chief of the Division of Clinical Genetics and Co-Director of the National Ovarian Cancer Early Detection Program at Northwestern University.

  read more

NOCC featured in Women Magazine
read more

President Proclaims September National Ovarian Cancer Awareness Month
read more

Austin Chapter's Run/Walk Raises Awareness!
read more

Dr. Oz joining the NOCC in Dallas on Saturday, August 20
read more

NOCC volunteer shares her story with Health Magazine
read more

Antibody that could detect early ovarian cancer detected
read more

Scientists Pinpoint Ovarian Cancer Gene
Is treatment on the way?
read more

How To Protect Yourself From Ovarian Cancer
read more

How You Can Take Action
read more

FDA Panel Opposes Avastin for Breast Cancer
read more

Drug Shortages Leave Cancer Patients at Risk
read more

DOXIL shortages to patients
(FDA) and healthcare professionals of a potential supply interruption we are managing with Centocor Ortho Biotech Products, L.P. recently informed the US Food and Drug Administration

DOXIL® 20-mg and 50-mg vials for injection that may result in shortages to patients over the next several weeks.

It may take several weeks to restock the market and there may be intermittent back orders during this period. It’s important to note that the supply situation is not related to product quality or safety.

Centocor Ortho Biotech Products, L.P is aware that patients rely on this product and are working to resupply the market as quickly as possible. During this time, treating physicians may need to make prescribing decisions based on individual patient circumstances. The Medical Information Center is available at 1-800-526-7736 for healthcare professionals who may have questions.

Additional information about DOXIL® can be found at www.DOXIL.com.read more

Prima Biomed Clinical Trials Offer Significant Upside
read more

Ovarian Cancer Starts Elsewhere, Study Says
read more

Experimental drug slows ovarian cancer growth
Survival increased in mouse model
read more

Chemo Plus Avastin Shows Benefit in Ovarian Cancer
read more

Ovarian Cancer Prognosis May Depend on Gene Mutations
Women with BRCA2 had best survival rate in study
read more

Dr. Joel Fuhrman's Cancer-Prevention Diet
read more

Ovarian cancer symptoms: What you need to know
read more

Lymph Node Biopsies Recommended
read more

Improved survival in non-Ashkenazi Jewish ovca patients with BRCA1 and BRCA2 gene mutations
read more

Study Pans Ovarian Cancer Screening Usefulness
read more

NJ Store Raises Funds for Awareness
read more

Hikers Raise Awareness for Ovarian Cancer
read more

Ovarian Cancer Featured on "The Dr. Oz Show"
read more

Ovarian Cancer Frequently Misdiagnosed
70% in NOCC Study Say Doctors Fail to Mention the Disease
read more

BEAT Campaign Spreads Awareness of Ovarian Cancer Symptoms
read more

Preventative Surgeries May Prevent Ovarian Cancer
read more

New Ovarian Cancer Test Shows Promise
read more

Genetic Marker Linked to Ovarian Cancer Risk
read more

The Voice of a Survivor
read more

Second Phase III Study Showed Avastin Slowed Ovarian Cancer Progression
read more

NOCC Raises Awareness at LPGA Championship
read more

Bride's Wedding is a Cancer Survivor's Way of Helping the Cause
read more

Positive Results From Phase 2 Clinical Study In Women with Platinum-Resistant Ovarian Cancer
Nektar Therapeutics announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant refractory ovarian cancer.   The response rate was higher than what would have been expected, and the median progression-free survival of eighteen weeks is longer than what would be expected in women with a median platinum-free interval of only one month.

The NOCC believes that the preliminary data of this study is encouraging.  We will provide more results on further studies as they become available. read more

Debulking Predicts Survival in Recurrent Ovarian Cancer
read more

Study: Avastin Slows Ovarian Cancer
read more

Abbott Receives FDA Clearance for New Ovarian Cancer Test
read more

Allergy sufferers less likely to develop cancer, scientists say
read more

Ovarian cancer screening shows promise
Study: New approach finds deadly tumors without too many false alarms
read more

Curcumin pretreatment helps destroy ovarian cancer cells
read more

Processed meat linked to higher ovarian cancer risk
read more

High Stress Levels May Promote Ovarian Cancer
read more

Screening Tool for Ovarian Cancer Identified
Four-biomarker panel has 86 percent sensitivity, 98 percent specificity for stages I and II disease
read more

Attacking Ignorance - Learn the Symptoms of Ovarian Cancer
read more

Aspirin, Other Pain Relievers Could Cut Risk Of Breast, Ovarian Cancer
read more

NOCC Talks to Developer of New OVA1 Test
read more

Genentech Announces Positive Results of Avastin Phase III Study in Women... with Advanced Ovarian Cancer
First Phase III study of an anti-angiogenic therapy in advanced ovarian cancer to meet primary endpoint
read more

Regular Aspirin Use Lowers the Risk of Developing Ovarian Cancer
read more

Understand Your Risks for Ovarian Cancer
read more

Pelvic Symptoms May Not Mean Ovarian Cancer
read more

Combo Test Might Spot Ovarian Cancer Early
read more

Combo Test Might Spot Ovarian Cancer Early
read more

Researchers make progress on early detection of ovarian cancer
read more

Most Ashkenazi Jewish women should be tested for breast cancer genes, study finds
read more

Arrayit Corporation Announces Manufacturing Breakthrough
read more

Study Offers New Option for Women With Ovarian Cancer
read more

Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
read more

Possible Ovarian Cancer Treatment Target Identified
read more

Diet Rich in Soy May Lower Risk of Ovarian Cancer
read more

Report: US Cancer Cases, Deaths, Continue to Decline
read more

OU Research Could Give Hope in Cancer Fight
Compound is Being Tested That May Lead to Preventative Drug
read more

Pertuzumab plus Gemzar® Active in Platinum-resistant Ovarian Cancer
read more

Ovarian cancer still lacks reliable early diagnostic test
read more

Leukemia Drug May Help Some Ovarian Cancer Patients
read more

U.S. Patent Office Issues Vermillion Patent for Biomarkers Detecting Ovarian Cancer
read more

Nanoparticles for gene therapy improve
read more

Court upholds right of scientists and patients to challenge gene patents
read more

AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
read more

Zeltia gets final EU okay for Yondelis drug
read more

Ovarian Cancer Drug Tested In San Antonio
read more

I Got Sick Then I Got Better
Theatre Review
read more

Partnership formed to detect ovarian cancer
read more

Researchers say rare metals can aid in fighting colon, ovarian cancer
read more

Color of hope: Teal ribbon shows support for women facing ovarian cancer
read more

New Ovarian Cancer Test Can Hone Referrals
read more

Walk In North Park Raises Ovarian Cancer Awareness
read more

The fight of her life
read more

The Enemy Within
NorthShore Magazine
read more

The FDA Rejects Another Good Cancer Drug
read more

Gene mutation is clue about cancer risks among Ashkenazi women
read more

Modified Chemo Regimen Effective in Advanced Ovarian Cancer
Women with advanced ovarian cancer lived longer and without their tumors growing after receiving a modified regimen of a standard chemotherapy drug combination, Japanese researchers reported last week.
read more

UPDATE 1, Nektar cancer drug shows promise in early trial
read more

Fertility Preservation Possible for Women with Ovarian Cancer
read more

Ovarian cancer walk raises $35,000
read more

Vermillion/Quest OVA1 Ovarian Cancer Risk Test Cleared by FDA
read more

New Research May Aid Earlier Detection Of Ovarian Cancer
read more

Blood test could improve survival in ovarian cancer patients
read more

New Treatment for Ovarian Cancer Looks Promising
read more

Join walk for ovarian cancer awareness
read more

Butterflies Released to Remember Ovarian Cancer Victims
read more

Hope Comes with Grant to Fight Ovarian Cancer
read more

Suicide Genes Help Slow Ovarian Tumor Growth in Mice
read more

Campaign For The Teal Ribbon
read more

Toward Earlier Detection of Ovarian Cancer
read more

Many Opt for Surgery to Lower Breast, Ovarian Cancer Risk
Women with BRCA gene mutations often choose preventive measures, study finds
read more

CAU and Georgia Tech collaborate to fight cancer
read more

Abbott, Fujirebio Co-Developing HE4/CA125 Dx to Improve Early Ovarian Cancer Detection
read more

Rare Ovarian Cancer Caused by One Genetic Mutation
read more

Low Ovarian Cancer Detection Rate by Symptoms Alone
Transvaginal ultrasound may be a more sensitive way to look for ovarian malignancy
read more

Symptoms absent in 80% of ovarian cancer patients
read more

Hormone Therapy Increases Odds of Ovarian Cancer
But risk remains low and decreases two years after stopping, study finds
read more

Menstrual Periods: Clues to Ovarian Cancer
Study Shows Risk of Death From Ovarian Cancer Linked to Overall Number of Ovulatory Cycles
read more

Does Race Affect Cancer Survival?
Breast Cancer Deaths Higher for Black Women Despite Equal Treatment
read more

Platypus Link to Ovarian Cancer
Researchers from the Royal Adelaide Hospital and University of Adelaide believe our oldest mammalian relative may help us to better understand ovarian cancer
read more

Holy Grail Of Cancer Research?
PARP Inhibitors May Ease Side Effects Of Chemotherapy
read more

New Cancer Drug Fights Tumors in Those With BRCA Mutations
Olaparib prevents malignant cells from repairing themselves, researchers say
read more

Ovarian Cancer Breakthrough Heralds New Era of Treatment
read more

Chickens are the only animals besides humans known to suffer from ovarian cancer
read more

Spare the Ovaries! What Women Should Ask Before a Hysterectomy
read more

Brave schoolgirl, eight, becomes youngest Briton to battle ovarian cancer
read more

Sharing Cancer Info May Be Empowering
Telling children about genetic risks fosters openness, expert says
read more

Early-Stage Ovarian Cancers Develop Less Aggressively
read more

Screening Tests Missing Early Signs of Ovarian Cancer
read more

Genetic Profile Found that Predicts Best Chemotherapy for Ovarian Cancers
read more

Addition Of Dasatinib To Standard Chemo Cocktail May Enhance Effect In Certain Ovarian Cancers
ScienceDaily (Apr. 25, 2009) - The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center. read more

Genetic Variations In MiRNA Processing Pathway And Binding Sites Help Predict Ovarian Cancer Risk
ScienceDaily (Apr. 23, 2009) - Genetic variations in the micro-RNA (miRNA) processing pathway genes and miRNA binding sites predict a woman’s risk for developing ovarian cancer and her prospects for survival, researchers from The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research. read more

Novogen's NV-128 Targets the MTOR Pathway to Block Differentiation And Induce Cell Death In Ovarian Cancer Stem Cells
(Apr. 21, 2009) - Data presented at the Annual Meeting of the American Association for Cancer Research in Denver has demonstrated that NV-128, a Novogen, Limited (ASX: NRT) (NASDAQ: NVGN) synthetic isoflavonoid compound, not only induces cell death in Ovarian Cancer Stem Cells (OCSCs), but also blocks their differentiation into structures which are required to support tumor growth. read more

Lpathomab®, Compelling New Preclinical Results - Ovarian Cancer
(Apr. 21, 2009) - Lpath, Inc. (OTCBB:LPTN), the category leader in bioactive-lipid-targeted therapeutics, reported compelling new in vivo and in vitro results relating to its preclinical drug candidate, Lpathomab, in various ovarian cancer studies. The results were presented today by Lpath scientists at the 100th Annual Meeting of the American Association for Cancer Research (AACR) in Denver, Colorado. read more

Hysterectomy: Spare Ovaries, Boost Health?
Ovary Removal Decreases Ovarian Cancer Risk but Increases Risk of Heart Disease and Death, Study Says
(Apr. 21, 2009) -- Ovary removal during a hysterectomy is often done to reduce the risk of ovarian cancer. But doing so also boosts the risk of heart disease and death long-term, according to a new study. read more

Gene variations could predict ovarian cancer risk
Variations within women's genes could predict risk for ovarian cancer, a new study has found
(Apr. 20, 2009) - Researchers at the University of Texas M.D. Anderson Cancer Center report that women who had eight or more of these unfavorable variations, or genotypes, were 4.5 times more likely to develop ovarian cancer, and women with six to eight of the genotypes were at twice the risk. The findings are being reported at the 100th annual meeting of the American Association for Cancer Research. read more

Researchers at Melbourne's Peter MacCallum Cancer Centre have discovered a genetic key that could lead to world-first cure for ovarian cancer.
(Apr. 20, 2009) - A major Australain study is investigating whether gene mutations are responsible for the cancer, which claims the lives of 800 Australian women each year. read more

Chemo Combo Shows Promise Against Ovarian Cancer
HealthDay News (Apr. 19, 2009) -- Adding the drug dasatinib to a standard, two-drug chemotherapy regimen for treating ovarian cancer boosted the effectiveness of the drugs in laboratory tests, new research shows. read more

Some Radiation Therapy Treatments Can Decrease Fertility
ScienceDaily (Apr. 12, 2009) - In female cancer patients of reproductive age, radiation treatment directly to the ovaries should be avoided because there is a direct relationship between certain types of radiation therapy and fertility problems, according to a review in the April 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO). read more

A mother's last wish: To see daughter wed
Volunteer organization helps cancer-stricken woman see dream wedding
(Apr. 9, 2009) - It’s a video wedding album that doesn’t leave a dry eye in the house - a mother giving away her daughter at a ceremony she might never had attended, at a financial cost she could never hope to meet. read more

Ovarian Cancer Screening Resulted in Many Unnecessary Surgeries
National Cancer Institute (Apr. 7, 2009) - Screening women for ovarian cancer often led to unnecessary surgeries and failed to detect the disease in its early stages, according to new results from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. The analysis focused on the 34,000 women in the NCI-sponsored trial who were screened annually for signs of ovarian cancer using transvaginal ultrasound and/or the CA-125 blood test. read more

Medicare Expands Coverage of Pet Scans as Cancer Diagnostic Tool
CMS' Coverage with Evidence Development Project Shows PET Scans as "Reasonable and Necessary" for Initial Treatment Decisions of Most Solid Tumor Cancers
(Apr. 6, 2009) - The Centers for Medicare & Medicaid Services (CMS) issued a final national coverage determination (NCD) to expand coverage for initial testing with positron emission tomography (PET) for Medicare beneficiaries who are diagnosed with and treated for most solid tumor cancers. read more

Yale Plans Closer Look at Exercise and Cancer
Studies will chart recovery of active women with breast or ovarian disease
HealthDay News  (Apr. 6, 2009) -- A Yale professor has received $7 million in federal grants for two studies into whether exercise affects ovarian and breast cancer recovery. read more

SNM Calls CMS PET Scan Decision a Major Benefit for Cancer Patients
National Oncologic PET Registry Provided Overwhelming Evidence of PET's Value
(Apr. 3, 2009) -SNM applauds today's decision by the Centers for Medicare and Medicaid Services (CMS) to expand coverage of positron emission tomography (PET) scans in the initial treatment strategy of patients with cancer. This decision was based, in large part, on compelling clinical evidence of the effectiveness of PET for cancer management and treatment contained in a comprehensive study known as the National Oncologic PET Registry (NOPR). read more

Catching Ovarian Cancer Early May Miss Aggressive Tumors
The finding casts the usefulness of screening into doubt, scientists say
HealthDay News  (Mar. 24, 2009) -- Early-stage ovarian cancers may be slower growing and less likely to spread than the more aggressive forms typically found in advanced stages of the disease, researchers report. read more

Morphotek ®, Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
PRNewswire (Mar. 23, 2009) - Morphotek ®, Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure. read more

Combo Screening Doesn't Spot Early Ovarian Cancer
Even finding it early may not save lives, researchers say
HealthDay News  (Mar. 20, 2009) -- A screening regimen that combines ultrasound and a blood test to detect CA125, a marker for ovarian cancer, fails to discover the cancer in its early stages and often results in unnecessary surgery, a new study shows. read more

Optimizing Chemotherapy with Bevacizumab for Ovarian Cancer
Information on Clinical Trial
read more